Her2-Positve Breast Cancer

A regimen of fulvestrant plus capivasertib may be effective in a subset of patients with breast cancer, according to results from the CAPItello-291 trial presented at San Antonio Breast Cancer Symposium.

Follow-up results from the ATEMPT trial showed that trastuzumab emtansine remained effective years after treatment in a subset of breast cancer patients, according to data presented at San Antonio Breast Cancer Symposium.

In this edition, the importance of vaccination after cell therapy, artificial intelligence may help predict cardiotoxicity, experimental breast cancer vaccine generates immune response, and more.

Healio spoke with Daphna Yael Spiegel, MD, MS, about screening, delays in diagnosis, and other ways the COVID-19 pandemic has impacted the breast cancer care continuum.

In this video, Stan Lipkowitz, MD, PhD, chief of the women's malignancies branch in the National Cancer Institute's Center for Cancer Research, discusses a session on the development of HER2 targeted therapies for breast cancer at AACR-NCI-EORTC.

Healio spoke with Debu Tripathy, MD, about the use of targeted therapies in breast cancer.

An updated analysis of the phase 2 DESTINY-Breast01 study showed fam-trastuzumab deruxtecan-nxki continued to benefit women with heavily pretreated HER2-positive metastatic breast cancer.